Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

MEAMyristoylethanolamide

A saturated fourteen-carbon N-acylethanolamine with no affinity for CB1; an assumed, undemonstrated entourage role.

Level of detail

C₁₆H₃₃NO₂

CAS 142-58-5

Family
Endocannabinoid or related mediatorEndocannabinoidome
Molar mass
271.40 g/mol

Updated on

In plain terms

Myristoylethanolamide belongs to the same chemical family as anandamide, but its fatty chain is saturated and it does not bind the cannabis receptors. It is assumed to act indirectly, by occupying the enzymes that destroy anandamide, but this has not been verified for it.

Receptors and activity

Target network

FAAHInhibitorClass datum, not measured for this molecule: N-acylethanolamines are hydrolysed by FAAH and, for some of them, by NAAA (Tsuboi 2018; Piomelli 2020). No constant has been published for myristoylethanolamide, and the competition with anandamide inferred from it has not been tested
  • Blocks or inhibits

The lower the cited value, the closer the target sits to MEA: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MEA.

Brain, side view
Body, front view
Blood

FAAHFAAH found in 7 regions of the body

  1. CortexpresentCortical pyramidal neurons1
  2. Basal gangliapresentStriatal neurons1
  3. HypothalamuspresentPresent in hypothalamic nuclei1
  4. CerebellumpresentPurkinje cells and cerebellar layers1
  5. BrainstempresentInferior olivary nuclei1
  6. Adipose tissuepresentExpressed in mature adipocytes2
  7. BonepresentPresent on osteoclasts3

Cited values

  1. FAAHInhibitorno measured value cited

    Class datum, not measured for this molecule: N-acylethanolamines are hydrolysed by FAAH and, for some of them, by NAAA (Tsuboi 2018; Piomelli 2020). No constant has been published for myristoylethanolamide, and the competition with anandamide inferred from it has not been tested

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Myristoylethanolamide is the saturated fourteen-carbon member of the N-acylethanolamine family, the one that counts anandamide among its unsaturated members and palmitoylethanolamide among its best-studied saturated ones. It shares with them the biosynthetic route, through a phospholipid precursor cleaved by NAPE-PLD, as well as the degrading enzymes, FAAH and NAAA (Tsuboi 2018; Piomelli 2020). It does not share their receptor pharmacology: the absence of unsaturations on its chain deprives it of the CB1 affinity that characterises anandamide. Watanabe and colleagues documented this dissociation in 1999 in three mouse models: no saturated ethanolamide, myristoylethanolamide included, produced catalepsy up to 40 mg/kg intravenously, where anandamide acted with a median effective dose of 6.0 mg/kg, and myristoylethanolamide did not prolong pentobarbital-induced sleep; it did, however, cause — like anandamide and its oleoyl and linoleoyl homologues — a significant but small hypothermia, of a few tenths of a degree, at 10 mg/kg. In a series devoted to pain, it had little or no effect on the formalin response, unlike palmitoylethanolamide (Calignano 2001). This profile places it among the entourage lipids rather than the messengers: competition for the enzymes that degrade the active endocannabinoids is plausible given the shared routes, but it has not been tested for this molecule, which carries no cannabinoid effect of its own.

History

Source
An endogenous compound present in trace amounts in animal tissues, where it is produced by the same enzymatic machinery as the other N-acylethanolamines (Tsuboi 2018). The molecule is also manufactured industrially: as myristamide MEA it is listed as a cosmetic ingredient (opacifier, antistatic agent, viscosity control, foam booster) and as a detergent additive, uses unrelated to its biological function (PubChem CID 8890, use classification).

Biosynthetic pathway

In vivo

The molecule is the saturated fourteen-carbon member of the N-acylethanolamine family, formed from myristic acid. Its production follows the route common to this family: an N-acyl-phosphatidylethanolamine (NAPE) is built by transfer of an acyl chain onto the amine function of a phosphatidylethanolamine, then releases the corresponding ethanolamide under the action of NAPE-PLD, further enzymes of this pathway having been identified more recently; degradation is carried out by FAAH and, for some substrates, by NAAA (Tsuboi 2018). No specific measurement of these steps has been published for myristoylethanolamide.

Classification

Family, origin and source verification

Family

Endocannabinoid or related mediator › Endocannabinoidome

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

No dedicated article.

References

Identifiers

Names

Common name
Myristoylethanolamide
IUPAC name
N-(2-hydroxyethyl)tetradecanamide
Other names
NMEA · N-myristoylethanolamine · 14:0 NAE · myristamide MEA

Identifiers

Formula
C₁₆H₃₃NO₂
CAS
142-58-5
PubChem CID
8890(new tab)
InChIKey
JHIXEZNTXMFXEK-UHFFFAOYSA-N
SMILES
CCCCCCCCCCCCCC(=O)NCCO

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.